Thank you to all the delegates, speakers and sponsors who supported the virtual Global Pharmaceutical Regulatory Affairs Summit.
The pandemic has created many challenges and a new way of life for many; this year’s virtual conference was one of the many changes 2020 has brought. However, my deepest thanks go to all those who attended the virtual Summit and continued to engage with the speakers, sponsors and fellow delegates in this new format.
Global Pharmaceutical Regulatory Affairs Summit has been going for many years, covering some of the hottest topics in telematics, eCTD and global regulations. At each conference, we strive to bring regulatory experts from across the pharmaceutical field to discuss the latest challenges in market access, regulatory management and pharmaceutical submissions. With regulatory strategies changing in the wake of the global pandemic and the move to create a more digital data driven regulatory structure, bringing experts from the different sectors of regulatory affairs is more crucial than ever.
With IDMP version 1 being released in February of this year, it was interesting to hear the impact this will have on industry and what steps are needed for industry to prepare for implementation. Whereas, in the global markets stream it was excellent to have regulatory agencies ANVISA and Russia present. With Brazil and Russia being two of the biggest regulatory markets at the moment getting the latest updates straight from NCA representatives was invaluable.
I have many personal highlights of this event, but the standout for me is the willingness of the speakers to throw themselves into a brand-new event format and continue to provide vital information to the delegates. With the world of virtual conferences with us for much longer than any of us had originally imagined, this enthusiasm has confirmed to me that in these strange times, we will still be able to create environments where the industry can learn from each other and continue to create a regulatory system with the main aim of getting new products to patients as quickly and efficiently as possible.
I hope you find this post event wrap of the event useful, and I look forward to seeing many of you at our 2021 conference.
Stay safe and well,
Jump to any article using the contents on the following page, or at any time using the Contents menu in the top left. There you can also download this report as a PDF.
A brief look at the headline statistics from the week.
An executive summary of the three key themes from the event explored through on-demand presentations.
We look back at the most popular panel discussion of the week, featuring Vada A Perkins (Bayer) , Kim Brownrigg (Accenture) and Rodrigo Palacios (Roche).
The week's most popular Q&A session discussed how eCTD v4.0 is expected to be implemented and optimised globally. This summary highlights the key points that were addressed.
A key highlight of the week was our Brazil Focused Q&A. This session answered some of industry’s burning questions regarding recent regulatory changes and processes in Brazil.
